Grant: Cat: Develop./validation of new biomedical techniques/technolo.-Infec.and Immun.
McMaster University
$300,000.00
Development of synthetic biology platforms for lariocidin, a new antibiotic candidate
EF 2024-25
Résumé
Many medicines are based on natural products - metabolites produced by living organisms. Natural products are the basis of drugs used for pain relief, cancer, immune suppression, and control of infectious diseases. Indeed, most antibiotics originate from natural products. While natural products are proven sources of new drugs, efforts to explore them have diminished over several decades due to challenges that include producing enough compound for development and their intrinsic chemical complexity. Recent advances in genomics and synthetic biology - the purposeful engineering of living systems - present new technology that can overcome some of the limitations of natural products.
Antibiotic resistance represents one of the most pressing challenges to modern medicine. Without antibiotics, treatment of bacterial infections becomes impossible. We have discovered a new peptide antibiotic, lariocidin, effective against a broad spectrum of bacterial pathogens, including drug-resistant strains. Lariocidin is not affected by existing resistance and is effective in an animal model of infection. To further develop lariocidin, we will establish synthetic biology platforms to increase the compound's production and facilitate our ability to engineer the synthesis of new-to-nature peptides. The success of this approach will provide new, widely applicable technology for peptide development and a lead molecule for new antibiotic development.
Programme
Cat: Develop./validation of new biomedical techniques/technolo.-Infec.and Immun.
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
513049
Name
Wright Gerard D
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Infection and Immunity
Theme2
Biomedical
Prcname2
Catalyst Grant: Development and validation of new biomedical techniques and technologies
Projecttitle
Development of synthetic biology platforms for lariocidin, a new antibiotic candidate
Programtype2
Operating Grants
Orgnameinp2
McMaster University
Cihramount2
$300,000
Cihrequipment2
$0
Programname2
Cat: Develop./validation of new biomedical techniques/technolo.-Infec.and Immun.
Keyworddelim
Antibiotic; Drug Discovery; Peptide; Pharmacology; Synthetic Biology
Abstract
Many medicines are based on natural products - metabolites produced by living organisms. Natural products are the basis of drugs used for pain relief, cancer, immune suppression, and control of infectious diseases. Indeed, most antibiotics originate from natural products. While natural products are proven sources of new drugs, efforts to explore them have diminished over several decades due to challenges that include producing enough compound for development and their intrinsic chemical complexity. Recent advances in genomics and synthetic biology - the purposeful engineering of living systems - present new technology that can overcome some of the limitations of natural products.
Antibiotic resistance represents one of the most pressing challenges to modern medicine. Without antibiotics, treatment of bacterial infections becomes impossible. We have discovered a new peptide antibiotic, lariocidin, effective against a broad spectrum of bacterial pathogens, including drug-resistant strains. Lariocidin is not affected by existing resistance and is effective in an animal model of infection. To further develop lariocidin, we will establish synthetic biology platforms to increase the compound's production and facilitate our ability to engineer the synthesis of new-to-nature peptides. The success of this approach will provide new, widely applicable technology for peptide development and a lead molecule for new antibiotic development.
Competitiondate
202407
Approvedterm2
2 yrs 0 mth
Pinamesdelim
Wright, Gerard D
Approvedterm
2 ans 0 mois
Cihrcontribution2
IG~ $100,000~ $0~III~ $200,000~ $0~